Reading UTMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track UTMD free→
Utah Medical Products, Inc. (UTMD)
NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Intact
$69.87+2.99%
Close 2026-06-15 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, and management's recent track record has been steady, with a capital-friendly approach. Earnings quality is mixed, and the sector backdrop is a headwind, which may pose challenges. Peer multiples imply a price about 4% below where it trades (it looks expensive on this basis); the read is fair. The outlook hinges on guidance changes and sector trends, particularly the performance of key Healthcare bellwethers. This read is provisional.
as of 2026-06-15
Quick facts
- Exchange
- NASDAQ
- Sector
- Health Care
- Industry
- Medical Instruments & Supplies
- Market cap
- $216.00M
- Employees
- —
- IPO date
- 1995-05-15
- Next earnings
- 2026-07-23
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 5 valuation methods, at three horizons. Current price $69.87. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfull
$67.30consensus
Range $31.72 – $68.63
vs price: +4% above
Method agreement — · 5 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearexpensive
$46.36consensus
Range $34.73 – $58.00
vs price: +51% above
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Aligned with peershigh confidence
At $70 UTMD trades at 21× p/e, in line with its 20× p/e peer median. Our $67 fair value reflects that, high confidence. Not investment advice.
Multiple (P/E)
20.7x
peer 19.9x · own history —
Premium
1.0x peer
Growth the price needs
4%
our forecast -3%
Our fair value
$67.30
range $38.40 – $68.63
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fullfair12-month view
What's priced inJustified
The market is pricing in roughly 4% near-term growth, in line with our forecast of about -3%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
87th pctl · Health Care
Earnings quality
neutralOver the trailing year it converted 1.23x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
39th pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
Management & capital allocation
stableEarnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Sector context
Intermediate · WeeklySector phase: health care is in maturing, with decelerating (~0.5 years in phase).
Sector regime (90d momentum): headwind.Secular epoch: Mature by revenue growth · theme biologics/biosimilars.headwind-9.9%sector vs S&P 500, 60d
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
AI cycle regime · market-wide
2-axis classifierLong-term · 1–3 yr
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Provisional
- Post-call reaction
- neutral
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-15
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Long-term · 1–3 yr
- #1
Maintain consistent financial results
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$98.
How much price usually moves either way.
On a bad day, this stock has moved -$215.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $1,577.
Deepest peak-to-trough drop in the last year.
moderateas of 2026-06-15
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- label change · valuation_labelsmall change
Valuation label changed from 'fair' to 'full'.
As of June 15, 2026, the valuation changed, moving from fair to full. Risk fell, indicating a decrease in overall risk. The sector backdrop remains a headwind, suggesting ongoing challenges in the market environment. The confidence level is low, indicating uncertainty in the current assessment.
as of 2026-06-15
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceQuartersactive 4d
Watch for sector revenue growth speeding up.
Why it matters: If revenue growth picks up, it may signal better times for the healthcare sector.
What confirms / what disproves
Confirms:Healthcare sector revenue growth returns to above 10% year over year.
Disproves:Revenue growth remains below 8% year over year.
Sector context
as of 2026-06-15
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for UTMD yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like ISRG, MDLN, and BDX keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting UTMD and other Healthcare names. Worth watching these names for early signals.
- If UTMD raises forward guidance on the next earnings call (currently NEW as of 2026-04-23), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If UTMD cuts guidance on the next call (currently NEW as of 2026-04-23), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like ISRG, MDLN, and BDX start missing or guiding lower, the Healthcare tailwind helping UTMD and other Healthcare names could fade. Watch these names for early warning.
- If UTMD misses again next quarter like this past one (a miss of -9% on the 2014-03-31 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-04-231mo agoItem 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION Attached hereto as Exhibit 99.1 and incorporated by reference herein is financial information for Utah Medical Products, Inc. for the three months ended March 31, 2026 and forward-looking statements relating to 2026 and beyond as presented in a press release dated April 23, 2026. The information in this report (including Exhibit 99.1) is being furnished pursuant to
Earnings preannouncement—
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.